GB201121557D0 - Process - Google Patents

Process

Info

Publication number
GB201121557D0
GB201121557D0 GB201121557A GB201121557A GB201121557D0 GB 201121557 D0 GB201121557 D0 GB 201121557D0 GB 201121557 A GB201121557 A GB 201121557A GB 201121557 A GB201121557 A GB 201121557A GB 201121557 D0 GB201121557 D0 GB 201121557D0
Authority
GB
United Kingdom
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GB201121557A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oxagen Ltd
Original Assignee
Oxagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oxagen Ltd filed Critical Oxagen Ltd
Priority to GB201121557A priority Critical patent/GB201121557D0/en
Publication of GB201121557D0 publication Critical patent/GB201121557D0/en
Priority to RS20150871A priority patent/RS54523B1/sr
Priority to MX2014007129A priority patent/MX342273B/es
Priority to PL12805725T priority patent/PL2791129T3/pl
Priority to SG11201402798RA priority patent/SG11201402798RA/en
Priority to AU2012351341A priority patent/AU2012351341B2/en
Priority to HRP20151422TT priority patent/HRP20151422T1/hr
Priority to EA201490998A priority patent/EA026617B1/ru
Priority to UAA201406835A priority patent/UA111868C2/uk
Priority to KR1020147017740A priority patent/KR102018929B1/ko
Priority to DK12805725.4T priority patent/DK2791129T3/en
Priority to ES12805725.4T priority patent/ES2557762T3/es
Priority to NZ626732A priority patent/NZ626732B2/en
Priority to PCT/GB2012/000903 priority patent/WO2013088108A1/en
Priority to BR112014014604-7A priority patent/BR112014014604B1/pt
Priority to PT128057254T priority patent/PT2791129E/pt
Priority to MEP-2015-218A priority patent/ME02348B/me
Priority to JP2014546621A priority patent/JP6300277B2/ja
Priority to US14/364,509 priority patent/US9102658B2/en
Priority to CA2859281A priority patent/CA2859281C/en
Priority to HK14110689.9A priority patent/HK1197671B/en
Priority to SI201230408T priority patent/SI2791129T1/sl
Priority to CN201280066207.8A priority patent/CN104114548B/zh
Priority to EP12805725.4A priority patent/EP2791129B1/en
Priority to HUE12805725A priority patent/HUE028257T2/en
Priority to ZA2014/04246A priority patent/ZA201404246B/en
Priority to IL233132A priority patent/IL233132A/en
Priority to CY20151101189T priority patent/CY1117087T1/el
Priority to SM201500327T priority patent/SMT201500327B/it
Priority to JP2017146700A priority patent/JP2018008985A/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Pulmonology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GB201121557A 2011-12-15 2011-12-15 Process Ceased GB201121557D0 (en)

Priority Applications (30)

Application Number Priority Date Filing Date Title
GB201121557A GB201121557D0 (en) 2011-12-15 2011-12-15 Process
HUE12805725A HUE028257T2 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethylindol-1-yl) acetic acid esters
BR112014014604-7A BR112014014604B1 (pt) 2011-12-15 2012-12-14 processo para a preparação de um composto, e, composto isolado e purificado
PT128057254T PT2791129E (pt) 2011-12-15 2012-12-14 Processo para a preparação de ésteres do ácido (5-fluoro-2-metil-3-quinolin-2-ilmetil-indol-1-il)-acético
PL12805725T PL2791129T3 (pl) 2011-12-15 2012-12-14 Sposób otrzymywania estrów kwasu (5-fluoro-2-metylo-3-chinolin-2-ylometyloindol-1-ilo)octowego
SG11201402798RA SG11201402798RA (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
AU2012351341A AU2012351341B2 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
HRP20151422TT HRP20151422T1 (hr) 2011-12-15 2012-12-14 Postupak za pripremu estera (5-fluoro-2-metil-3-hinolin-2-ilmetil-indol-1-il)-octene kiseline
EA201490998A EA026617B1 (ru) 2011-12-15 2012-12-14 Способ получения сложных эфиров (5-фтор-2-метил-3-хинолин-2-илметил-индол-1-ил)уксусной кислоты
UAA201406835A UA111868C2 (uk) 2011-12-15 2012-12-14 Спосіб одержання естерів (5-фтор-2-метил-3-хінолін-2-ілметиліндол-1-іл)-оцтової кислоти
KR1020147017740A KR102018929B1 (ko) 2011-12-15 2012-12-14 (5-플루오로-2-메틸-3-퀴놀린-2-일메틸-인돌-1-일)-아세트산에스테르의 제조 방법
DK12805725.4T DK2791129T3 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl) -acetic acid esters
ES12805725.4T ES2557762T3 (es) 2011-12-15 2012-12-14 Proceso para la preparación de ésteres de ácido (5-fluoro-2-metil-3-quinolin-2-ilmetil-indol-1-il)-acético
NZ626732A NZ626732B2 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
PCT/GB2012/000903 WO2013088108A1 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
RS20150871A RS54523B1 (sr) 2011-12-15 2012-12-14 Postupak za pripremu estara (5-fluoro-2-metil-3-hinolin-2-ilmetil-indol-1-il)-sirćetne kiseline
MEP-2015-218A ME02348B (me) 2011-12-15 2012-12-14 POSTUPAK ZA PRIPREMU ESTARA (5-FLUORO-2-METIL-3-HINOLIN-2-lL METIL-INDOL-1-IL)-SIRĆETNE KISELINE
SI201230408T SI2791129T1 (sl) 2011-12-15 2012-12-14 Postopek za pripravo estrov (5-fluoro-2-metil-3-kinolin-2-ilmetilindol-1-il)-ocetne kisline
EP12805725.4A EP2791129B1 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
US14/364,509 US9102658B2 (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-y1)-acetic acid esters
CA2859281A CA2859281C (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
HK14110689.9A HK1197671B (en) 2011-12-15 2012-12-14 Process for the preparation of (5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-yl)-acetic acid esters
MX2014007129A MX342273B (es) 2011-12-15 2012-12-14 Proceso para la preparacion de esteres de acido (5-fluoro-2-metil-3-quinolina-2-ilmetil-indol-1-il)-acetico.
CN201280066207.8A CN104114548B (zh) 2011-12-15 2012-12-14 (5-氟-2-甲基-3-喹啉-2-基甲基-吲哚-1-基)-乙酸酯的制备方法
JP2014546621A JP6300277B2 (ja) 2011-12-15 2012-12-14 （５−フルオロ−２−メチル−３−キノリン−２−イルメチル−インドール−１−イル）−酢酸エステルの製造のための方法
ZA2014/04246A ZA201404246B (en) 2011-12-15 2014-06-09 Process for the preparation of(5-fluoro-2-methyl-3-quinolin-2-ylmethyl-indol-1-1yl)-acetic acid
IL233132A IL233132A (en) 2011-12-15 2014-06-15 Process for Preparation of Esters of 5-Fluoro-2-Methyl-3-Quinoline-2-Illmethylindole-1-Ill-Acetic Acid
CY20151101189T CY1117087T1 (el) 2011-12-15 2015-12-23 Διαδικασια για την παρασκευη εστερων (5-φθορο-2-μεθυλο-3-κινολιν-2-υλμεθυλ-ινδoλ-1-υλ)- οξικου οξεος
SM201500327T SMT201500327B (it) 2011-12-15 2015-12-23 Procedimento per la preparazione di esteri di acido (5-fluoro-2-metil-3-chinolin-2-ilmetil-indol-1-il)-acetico
JP2017146700A JP2018008985A (ja) 2011-12-15 2017-07-28 （５−フルオロ−２−メチル−３−キノリン−２−イルメチル−インドール−１−イル）−酢酸エステルの製造のための方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB201121557A GB201121557D0 (en) 2011-12-15 2011-12-15 Process

Publications (1)

Publication Number Publication Date
GB201121557D0 true GB201121557D0 (en) 2012-01-25

Family

ID=45560499

Family Applications (1)

Application Number Title Priority Date Filing Date
GB201121557A Ceased GB201121557D0 (en) 2011-12-15 2011-12-15 Process

Country Status (27)

Country Link
US (1) US9102658B2 (enExample)
EP (1) EP2791129B1 (enExample)
JP (2) JP6300277B2 (enExample)
KR (1) KR102018929B1 (enExample)
CN (1) CN104114548B (enExample)
AU (1) AU2012351341B2 (enExample)
BR (1) BR112014014604B1 (enExample)
CA (1) CA2859281C (enExample)
CY (1) CY1117087T1 (enExample)
DK (1) DK2791129T3 (enExample)
EA (1) EA026617B1 (enExample)
ES (1) ES2557762T3 (enExample)
GB (1) GB201121557D0 (enExample)
HR (1) HRP20151422T1 (enExample)
HU (1) HUE028257T2 (enExample)
IL (1) IL233132A (enExample)
ME (1) ME02348B (enExample)
MX (1) MX342273B (enExample)
PL (1) PL2791129T3 (enExample)
PT (1) PT2791129E (enExample)
RS (1) RS54523B1 (enExample)
SG (1) SG11201402798RA (enExample)
SI (1) SI2791129T1 (enExample)
SM (1) SMT201500327B (enExample)
UA (1) UA111868C2 (enExample)
WO (1) WO2013088108A1 (enExample)
ZA (1) ZA201404246B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) 2011-12-15 2012-01-25 Oxagen Ltd Process
GB201322273D0 (en) * 2013-12-17 2014-01-29 Atopix Therapeutics Ltd Process
GB201407807D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) * 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
EP3902795A1 (en) 2018-12-27 2021-11-03 Chiesi Farmaceutici S.p.A. Pharmaceutical composition comprising spherical agglomerates of timapiprant
CN111978245A (zh) * 2020-09-15 2020-11-24 上海毕得医药科技有限公司 一种3-氟-2-异丁基吡啶的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0415437A (pt) 2003-10-14 2006-12-05 Oxagen Ltd composto, processo para a preparação e uso do mesmo, composição farmacêutica, processo para a preparação da mesma, e, produto
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
GB0504150D0 (en) * 2005-03-01 2005-04-06 Oxagen Ltd Microcrystalline material
GB0505048D0 (en) 2005-03-11 2005-04-20 Oxagen Ltd Compounds with PGD antagonist activity
US7188489B2 (en) 2005-04-12 2007-03-13 Martello Russell A Portable air conditioner
GB0605743D0 (en) * 2006-03-22 2006-05-03 Oxagen Ltd Salts with CRTH2 antagonist activity
MX2009000801A (es) 2006-07-22 2009-02-03 Oxagen Ltd Compuestos que tienen actividad antagonista crth2.
US20110124683A1 (en) 2007-11-13 2011-05-26 Oxagen Limited Use of CRTH2 Antagonist Compounds
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
DK2250161T3 (da) 2008-01-18 2014-01-27 Atopix Therapeutics Ltd Forbindelser med CRTH2-antagonistaktivitet
US8168673B2 (en) 2008-01-22 2012-05-01 Oxagen Limited Compounds having CRTH2 antagonist activity
JP2011509990A (ja) 2008-01-22 2011-03-31 オキサジェン リミテッド Ｃｒｔｈ２アンタゴニスト活性を有する化合物
US20130052190A1 (en) 2011-02-22 2013-02-28 Oxagen Limited CRTH2 Antagonists for Treatment of Eosinophilic Diseases and Conditions
GB201103837D0 (en) 2011-03-07 2011-04-20 Oxagen Ltd Amorphous (5-Fluoro-2-Methyl-3-Quinolin-2-Ylmethyl-Indol-1-Yl)-acetic acid
GB201121557D0 (en) * 2011-12-15 2012-01-25 Oxagen Ltd Process
SG11201402796SA (en) 2011-12-16 2014-06-27 Atopix Therapeutics Ltd Combination of crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis

Also Published As

Publication number Publication date
CN104114548A (zh) 2014-10-22
IL233132A (en) 2015-09-24
NZ626732A (en) 2015-09-25
ZA201404246B (en) 2016-10-26
AU2012351341B2 (en) 2017-08-24
SG11201402798RA (en) 2014-06-27
EA201490998A1 (ru) 2014-11-28
SI2791129T1 (sl) 2016-02-29
EP2791129B1 (en) 2015-10-07
EP2791129A1 (en) 2014-10-22
ES2557762T3 (es) 2016-01-28
MX2014007129A (es) 2014-09-04
HUE028257T2 (en) 2016-12-28
MX342273B (es) 2016-09-21
CY1117087T1 (el) 2017-04-05
HRP20151422T1 (hr) 2016-02-26
UA111868C2 (uk) 2016-06-24
AU2012351341A1 (en) 2014-07-24
ME02348B (me) 2016-06-20
SMT201500327B (it) 2016-02-25
US9102658B2 (en) 2015-08-11
HK1197671A1 (zh) 2015-02-06
PT2791129E (pt) 2016-01-26
JP6300277B2 (ja) 2018-03-28
JP2018008985A (ja) 2018-01-18
PL2791129T3 (pl) 2016-05-31
DK2791129T3 (en) 2015-12-14
BR112014014604B1 (pt) 2021-01-12
CN104114548B (zh) 2016-01-20
EA026617B1 (ru) 2017-04-28
KR102018929B1 (ko) 2019-09-05
RS54523B1 (sr) 2016-06-30
KR20140113927A (ko) 2014-09-25
US20140350264A1 (en) 2014-11-27
CA2859281C (en) 2020-10-27
BR112014014604A2 (pt) 2017-06-13
WO2013088108A1 (en) 2013-06-20
IL233132A0 (en) 2014-08-03
CA2859281A1 (en) 2013-06-20
JP2015500325A (ja) 2015-01-05

Similar Documents

Publication Publication Date Title
GB201121308D0 (en) Process
GB201103499D0 (en) Process
GB201111595D0 (en) Improved process
GB201107072D0 (en) Process
PL2793599T3 (pl) Sposób
GB201218123D0 (en) Process
ZA201305221B (en) Process
GB201121557D0 (en) Process
GB201112051D0 (en) Process
GB201107073D0 (en) Process
IL229126A0 (en) process
GB201115218D0 (en) Novel process
GB201218121D0 (en) Process
GB201218124D0 (en) Process
PT2726454T (pt) Processo
GB201112370D0 (en) Process
GB201103092D0 (en) Process
GB201107221D0 (en) Process
GB201105537D0 (en) New process
SG11201403684YA (en) Process
GB2493491B (en) Process
GB201208567D0 (en) Process
GB201121560D0 (en) Process
GB201107193D0 (en) Process
GB201107198D0 (en) Process

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)